Advanced Immunoclinical Phenotyping of Rejection in Lung Transplant

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

1,200

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2038

Conditions
Chronic Rejection of Lung Transplant
Interventions
DIAGNOSTIC_TEST

Lung transplant recipient without MRI imaging

Patients who received lung transplant and undergoing surveillance follow-up at 1, 3, 6, 12, 24 months after the date of lung transplant, but without consenting to be evaluated by hyperbolized gas MRI. Bronchoscopy sampling will be performed per usual lung transplant team protocol.

DRUG

Lung transplant recipient with MRI imaging

Patients who received lung transplant and undergoing surveillance follow-up at 1, 3, 6, 12, 24 months after the date of lung transplant and with consenting to be evaluated by hyperbolized has MRI. Bronchoscopy sampling will be guided by the results of the hyper polarized gas MRI, different from the usual lung transplant team protocol. Administration of hyper polarized gas MRI is under FDA regulation by IND #129769 (PI, Yun Michael Shim, MD)

Trial Locations (1)

22908

University of Virginia Health System, Charlottesville

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

University of Virginia

OTHER

NCT03697395 - Advanced Immunoclinical Phenotyping of Rejection in Lung Transplant | Biotech Hunter | Biotech Hunter